For Immediate Release

Kalm Therapeutics Receives a Therapeutics Development Fund Grant from Station 41 at Southern Research

Birmingham, AL and Huntsville, AL – March 24, 2025

Kalm Therapeutics (Huntsville, AL), an immune and inflammation-focused biopharma company, is excited to announce a significant grant from Southern Research's Therapeutics Development Fund (TDF). The award will support an *in vivo* GLP study on our topical patch system, working with SR's *in vivo* studies team. The Company's focus is to use immune modulating small molecules in its gentle adhesive patch to treat inflammatory skin conditions such as atopic dermatitis (eczema) while avoiding steroid use. Atopic dermatitis, psoriasis, and prurigo nodularis are in focus.

The TDF was recently established by Southern Research, a non-profit scientific research organization focused on drug discovery and development. The goal of the Therapeutics Development Fund is to enhance the life sciences and biotechnology industry in Alabama by supporting the state's leading innovators and its growing ecosystem in this sector, especially those pursuing high-potential projects that address critical medical challenges.

"The awarded grant will enable Kalm Therapeutics to accelerate its groundbreaking work and position the company for an FDA Investigational New Drug submission later this year," said AJ Singhal, Founder and CEO of Kalm Therapeutics. "We are focused on providing a safer and easier treatment alternative to steroids for the 20 million patients suffering from localized atopic dermatitis and psoriasis."

Station 41 (Birmingham, AL), a new commercialization engine for life sciences and biotechnology located at Southern Research and led by the University of Alabama at Birmingham (UAB) Harbert Institute for Innovation and Entrepreneurship, is pleased to support this work as well as help connect the Huntsville and Birmingham ecosystems. "As a Scientist to CEO across my career, it is all about ecosystem building and support for me now," said Dr. Erik Schwiebert, Director of Station 41. "We want our long simmering ecosystem to bubble and boil and do so across Alabama. We are also grateful for the underlying support from the Innovate Alabama Tax Credit Program to drive this project."

For more information about Station 41, please visit Station 41.bio

For more information about Kalm Therapeutics, please visit https://kalmtherapeutics.com, <u>Eczema</u> Patch